113 related articles for article (PubMed ID: 34290908)
1. An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC).
Guo H; Li B; Diao L; Wang H; Chen P; Jiang M; Zhao L; He Y; Zhou C
Oncoimmunology; 2021; 10(1):1947665. PubMed ID: 34290908
[TBL] [Abstract][Full Text] [Related]
2. Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review.
Wei Y; Wang L; Jin Z; Jia Q; Brcic L; Akaba T; Chu Q
Transl Lung Cancer Res; 2024 Mar; 13(3):635-653. PubMed ID: 38601447
[TBL] [Abstract][Full Text] [Related]
3. Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers.
Ding K; Peng Z; Xu Y
Ther Adv Med Oncol; 2024; 16():17588359241249041. PubMed ID: 38716479
[TBL] [Abstract][Full Text] [Related]
4. The diversity of inhibitory receptor co-expression patterns of exhausted CD8
Rao Y; Qiu K; Song Y; Mao M; Feng L; Cheng D; Li J; Zhang Z; Zhang Y; Shao X; Pang W; Wang Y; Chen X; Jiang C; Wu S; Yu S; Liu J; Wang H; Peng X; Yang L; Chen L; Mu X; Zheng Y; Xu W; Liu G; Chen F; Yu H; Zhao Y; Ren J
iScience; 2024 May; 27(5):109668. PubMed ID: 38655196
[TBL] [Abstract][Full Text] [Related]
5. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Chen P; Zhao L; Wang H; Zhang L; Zhang W; Zhu J; Yu J; Zhao S; Li W; Sun C; Wu C; He Y; Zhou C
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362829
[TBL] [Abstract][Full Text] [Related]
6. Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse.
Guo H; Diao L; Zhou X; Chen JN; Zhou Y; Fang Q; He Y; Dziadziuszko R; Zhou C; Hirsch FR
Transl Lung Cancer Res; 2021 Jun; 10(6):2452-2474. PubMed ID: 34295654
[TBL] [Abstract][Full Text] [Related]
7. Risk-score model to predict prognosis of malignant airway obstruction after interventional bronchoscopy.
Jiang M; Xu H; Yu D; Yang L; Wu W; Wang H; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; Zhang L; Hou L; Zhang H; Gu Y; He Y
Transl Lung Cancer Res; 2021 Jul; 10(7):3173-3190. PubMed ID: 34430356
[TBL] [Abstract][Full Text] [Related]
8. Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level.
Wu Y; Yang S; Ma J; Chen Z; Song G; Rao D; Cheng Y; Huang S; Liu Y; Jiang S; Liu J; Huang X; Wang X; Qiu S; Xu J; Xi R; Bai F; Zhou J; Fan J; Zhang X; Gao Q
Cancer Discov; 2022 Jan; 12(1):134-153. PubMed ID: 34417225
[TBL] [Abstract][Full Text] [Related]
9. Collection on reports of molecules linked to epithelial-mesenchymal transition in the process of treating metastasizing cancer: a narrative review.
Cai Y; Wang B; Li B; Huang X; Guo H; Liu Y; Chen B; Zhao S; Wu S; Li W; Wang L; Jia K; Wang H; Chen P; Jiang M; Tang X; Qi H; Dai C; Ye J; He Y
Ann Transl Med; 2021 Jun; 9(11):946. PubMed ID: 34350261
[TBL] [Abstract][Full Text] [Related]
10. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
11. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J
Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508
[TBL] [Abstract][Full Text] [Related]
12. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and Prognostic Features of 67 Cases with Pulmonary Sarcomatoid Carcinoma: An 18-Year Single-Centre Experience.
Ferhatoglu F; Amirov F; Ozkan B; Kara M; Toker A; Ak N; Aydın E; Paksoy N; Yilmazbayhan D; Aydiner A
Oncol Res Treat; 2021; 44(11):590-601. PubMed ID: 34555834
[TBL] [Abstract][Full Text] [Related]
14. Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer.
Song W; Ren J; Xiang R; Kong C; Fu T
Oncoimmunology; 2021; 10(1):1987636. PubMed ID: 34676149
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Abscopal Effect of Microwave Ablation in a Patient With Advanced Squamous NSCLC and Resistance to Immunotherapy.
Shao C; Yang M; Pan Y; Xie D; Chen B; Ren S; Zhou C
Front Immunol; 2021; 12():696749. PubMed ID: 34413851
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of the DNA Repair Gene Signature in Head and Neck Squamous Cell Carcinoma.
Ming R; Wang E; Wei J; Shen J; Zong S; Xiao H
Front Oncol; 2021; 11():710694. PubMed ID: 34395285
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.
Galland L; Le Page AL; Lecuelle J; Bibeau F; Oulkhouir Y; Derangère V; Truntzer C; Ghiringhelli F
Oncoimmunology; 2021; 10(1):1957603. PubMed ID: 34377595
[TBL] [Abstract][Full Text] [Related]
18. Multi-Omics Integrative Bioinformatics Analyses Reveal Long Non-coding RNA Modulates Genomic Integrity via Competing Endogenous RNA Mechanism and Serves as Novel Biomarkers for Overall Survival in Lung Adenocarcinoma.
Wang Z; Ren Z; Li R; Ge J; Zhang G; Xin Y; Qu Y
Front Cell Dev Biol; 2021; 9():691540. PubMed ID: 34368141
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy.
Liu J; Wang Y; Mei J; Nie S; Zhang Y
Front Cell Dev Biol; 2021; 9():671736. PubMed ID: 34368124
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.
Scott JG; Sedor G; Ellsworth P; Scarborough JA; Ahmed KA; Oliver DE; Eschrich SA; Kattan MW; Torres-Roca JF
Lancet Oncol; 2021 Sep; 22(9):1221-1229. PubMed ID: 34363761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
